Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPS COMPASS Pathways	$4.80 +7.1%	$4.01	$2.49 ▼ $8.54	$449.10M	2.25	920,182 shs	3.06 million shs
MBX MBX Biosciences	$10.28 +1.8%	$10.62	$4.81 ▼ $27.50	$343.60M	N/A	249,270 shs	184,797 shs
PGEN Precigen	$1.49 +4.9%	$1.43	$0.65 ▼ $2.17	$439.82M	1.84	1.36 million shs	1.52 million shs
SAVA Cassava Sciences	$2.07	$1.83	$1.15 ▼ $42.20	$100.00M	-1.99	3.02 million shs	580,895 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPS COMPASS Pathways	+7.14%	+4.58%	+10.34%	+62.16%	-25.35%
MBX MBX Biosciences	+1.78%	-6.03%	-15.39%	+28.98%	+1,027,999,900.00%
PGEN Precigen	+4.93%	-0.67%	+9.56%	-17.22%	-5.10%
SAVA Cassava Sciences	0.00%	-0.96%	0.00%	-25.00%	-89.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPS COMPASS Pathways	2.0917 of 5 stars	3.5	3.0	0.0	1.3	0.8	0.6
MBX MBX Biosciences	2.0617 of 5 stars	3.5	0.0	0.0	0.0	3.3	0.6
PGEN Precigen	4.0866 of 5 stars	3.5	1.0	4.7	3.2	1.7	0.6
SAVA Cassava Sciences	3.8482 of 5 stars	3.3	3.0	4.7	1.1	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPS COMPASS Pathways	3.00	Buy	$18.83	292.36% Upside
MBX MBX Biosciences	3.00	Buy	$37.50	264.79% Upside
PGEN Precigen	3.00	Buy	$6.00	302.68% Upside
SAVA Cassava Sciences	2.50	Moderate Buy	$54.50	2,532.85% Upside

Current Analyst Ratings Breakdown

Latest SAVA, MBX, CMPS, and PGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/15/2025	PGEN Precigen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/13/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
4/10/2025	MBX MBX Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
4/10/2025	MBX MBX Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00 ➝ $44.00
4/10/2025	MBX MBX Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$38.00
3/28/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/25/2025	SAVA Cassava Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$2.00 ➝ $2.00
3/20/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	$3.92M	112.20	N/A	N/A	$0.13 per share	11.46
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	$3.03 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPS COMPASS Pathways	-$155.12M	-$1.99	N/A	N/A	N/A	N/A	-81.75%	-59.42%	7/30/2025 (Estimated)
MBX MBX Biosciences	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	-$126.24M	-$0.56	N/A	N/A	N/A	-3,728.87%	-279.20%	-79.74%	8/13/2025 (Estimated)
SAVA Cassava Sciences	-$24.34M	-$1.50	N/A	N/A	N/A	N/A	-87.72%	-72.05%	8/14/2025 (Estimated)

Latest SAVA, MBX, CMPS, and PGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	PGEN Precigen	-$0.08	-$0.07	+$0.01	-$0.18	$0.50 million	$1.34 million
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A
5/8/2025	Q1 2025	SAVA Cassava Sciences	N/A	-$0.48	N/A	-$0.48	N/A	N/A
3/19/2025	Q4 2024	PGEN Precigen	-$0.06	-$0.04	+$0.02	-$0.06	$1.30 million	$1.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPS COMPASS Pathways	0.11	10.18	10.18
MBX MBX Biosciences	N/A	N/A	N/A
PGEN Precigen	N/A	3.53	3.53
SAVA Cassava Sciences	N/A	9.08	9.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPS COMPASS Pathways	46.19%
MBX MBX Biosciences	N/A
PGEN Precigen	33.51%
SAVA Cassava Sciences	38.05%

Insider Ownership

Company	Insider Ownership
CMPS COMPASS Pathways	3.93%
MBX MBX Biosciences	52.19%
PGEN Precigen	47.10%
SAVA Cassava Sciences	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPS COMPASS Pathways	120	93.56 million	89.89 million	Optionable
MBX MBX Biosciences	36	33.42 million	N/A	N/A
PGEN Precigen	190	295.18 million	156.15 million	Optionable
SAVA Cassava Sciences	30	48.31 million	47.15 million	Optionable

SAVA, MBX, CMPS, and PGEN Headlines

Recent News About These Companies

Two Sigma Investments LP Has $1.33 Million Position in Cassava Sciences, Inc. (NASDAQ:SAVA)

June 5, 2025 | marketbeat.com

Two Sigma Advisers LP Invests $1.43 Million in Cassava Sciences, Inc. (NASDAQ:SAVA)

June 1, 2025 | marketbeat.com

Cassava gives AI firm access to its collection of GPUs

May 19, 2025 | htxt.co.za

Cassava gives AI firm access to its collection of GPUs

May 19, 2025 | htxt.co.za

Cassava partners with Zindi to give African AI developers better tools

May 16, 2025 | techzim.co.zw

Cassava Sciences Inc.

May 16, 2025 | barrons.com

5 ON YOUR SIDE: Lead levels in cassava flour

May 15, 2025 | kstp.com

Cassava Technologies, Zindi collaborate on AI services

May 12, 2025 | msn.com

Cassava Technologies and Zindi collaborate to showcase African A.I. innovation

May 12, 2025 | thezimbabwemail.com

Cassava Technologies and Zindi Partner to Supercharge Africa’s AI and GPU Ecosystem

May 12, 2025 | devdiscourse.com

New report finds concerning levels of lead in popular cassava items

May 12, 2025 | yahoo.com

Cassava takes next step for African AI

May 12, 2025 | htxt.co.za

Cassava Technologies and Zindi collaborate to showcase African Artificial Intelligence (AI) innovation

May 12, 2025 | zawya.com

Cassava Reports Q1 2025 Financials Results, Provides Business Update

May 9, 2025 | finance.yahoo.com

Zindi Teams Up with Cassava to Spotlight African AI Talent

May 6, 2025 | msn.com

Zindi Supports Cassava Technologies with 85 K Zindians to showcase African AI innovation

May 5, 2025 | msn.com

Cassava Consciousness from The Tamarind Galaxy part two

May 1, 2025 | modernghana.com

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

May 1, 2025 | globenewswire.com

Targeted and random mutagenesis of cassava brown streak disease susceptibility factors reveal molecular determinants of disease severity

April 30, 2025 | elifesciences.org

Cassava Sciences appoints new SVP of Clinical Development

April 23, 2025 | investing.com

Cassava Sciences chief medical officer James Kupiec to retire

April 22, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SAVA, MBX, CMPS, and PGEN Company Descriptions

COMPASS Pathways NASDAQ:CMPS

$4.80 +0.32 (+7.14%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$4.96 +0.17 (+3.44%)

As of 06/18/2025 07:52 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

MBX Biosciences NYSE:MBX

$10.28 +0.18 (+1.78%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$10.28 0.00 (-0.05%)

As of 06/18/2025 04:04 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Precigen NASDAQ:PGEN

$1.49 +0.07 (+4.93%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.48 -0.01 (-1.01%)

As of 06/18/2025 07:57 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Cassava Sciences NASDAQ:SAVA

$2.07 0.00 (0.00%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$2.06 -0.01 (-0.48%)

As of 06/18/2025 07:59 PM Eastern

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time